To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
To assess the pharmacokinetics of AZD1656, and its metabolite, in type 2 diabetes mellitus
patients with varying degrees of renal impairment and to compare the results with those in
patients with normal renal function.